All Blogs
Dec 24, 2025
Johnson & Johnson Secures FDA Approval for TRUFILL® n-BCA in Chronic Subdural Hematoma Treatment; Abbott’s Volt™ Pulsed Field Ablation System Gains FDA Approval for AF Patients; Medicus Pharma Ltd. Partners with Reliant AI to Develop an Artificial Intelligence–Driven Clinical Data Analytics Platform; Solventum Finalized the Acquisition of Acera Surgical; Envoy Medical Hits Critical Enrollment Benchmark in Acclaim® Cochlear Implant Pivotal Trial; Galaxy Therapeutics Completes Enrollment in Pivotal SEAL IT IDE Study
Johnson & Johnson Received FDA Approval for TRUFILL n BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma On December 18, 2025, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) had approved an expanded i...
Read More...
Dec 23, 2025
Novo Nordisk Seeks FDA Approval for CagriSema; EU Approves Subcutaneous Self-administration of SAPHNELO via Pre-filled Pen for SLE; Cytokinetics Secures FDA Approval of MYQORZO for Adult Patients with Symptomatic Obstructive HCM; Boehringer’s JASCAYD Wins FDA Approval for Adult Pulmonary Fibrosis; BioMarin to Acquire Amicus for $4.8B, Advancing Long-Term Growth in Rare Diseases
Novo Nordisk Submits CagriSema for FDA Review as a Once-weekly GLP-1–amylin Combination Therapy for Weight Management Novo Nordisk has officially filed a New Drug Application (NDA) with the U.S. FDA for CagriSema, a once-weekly subcutaneous injection intended for chronic weight management. CagriSema represents a...
Read More...
Dec 18, 2025
BD Broadens BD MAX™ System Menu with IVDR-Certified VIASURE Assays; OrthAlign Broadens the Lantern® Hip Platform for Posterior Approach Total Hip Arthroplasty; Bioretec Received FDA Breakthrough Device Designation for the Remeos™ Drillpin; Medivis Achieves First FDA Authorization for AR Navigation in Neurosurgery; Cerapedics Publishes 24-Month ASPIRE Clinical Outcomes in Spine Journal; Acumed’s Acu-Loc NEXT System Debuts in First Wrist Fixation Surgery at Duke University Hospital
BD Expanded BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec On December 15, 2025, BD (Becton, Dickinson and Company), a leading global medical technology company, announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics po...
Read More...
Dec 22, 2025
CAR-T Beyond Cancer: Resetting Immunity in Autoimmune Diseases
Chimeric Antigen Receptor T-cell (CAR-T) therapy has established itself as one of the most disruptive innovations in modern medicine. Since the first approval in 2017, CAR-T therapies have transformed outcomes in hematologic malignancies, achieving deep, durable remissions in patient populations previously resistan...
Read More...
Dec 17, 2025
The Automated Eye: How AI-Driven Diagnostics are Reshaping the Future of Medical Imaging
Artificial intelligence (AI) has rapidly emerged as a transformative force in medical imaging, revolutionizing disease detection, diagnosis, and monitoring. From radiology to pathology, AI algorithms are enhancing image interpretation, improving diagnostic accuracy, and streamlining clinical workflows across health...
Read More...
Dec 19, 2025
WASKYRA Wins FDA Approval, Marking a Historic Leap for Rare Disease Gene Therapies
In a landmark decision on December 10, 2025, the FDA approved WASKYRA (etuvetidigene autotemcel), marking a transformative milestone in the treatment of Wiskott-Aldrich syndrome—a rare, life-threatening genetic blood disorder. This approval represents not only a significant advancement in gene therapy but also a hi...
Read More...
Dec 16, 2025
Pilatus Biosciences Advances PLT012 Into the Clinic Following FDA IND Clearance; ENHERTU + pertuzumab Receives US Approval as the First New First-line Option in a Decade for HER2-positive Metastatic Breast Cancer; Sanofi Reports on Tolebrutinib Development in Primary Progressive MS; Gilead Reports Positive Phase 3 Results for Bictegravir–Lenacapavir Investigational HIV Therapy; argenx Announces Study Update for UplighTED Program of Efgartigimod SC in Thyroid Eye Disease
Pilatus Biosciences Receives FDA IND Clearance for PLT012, a Novel Anti-CD36 Metabolic Checkpoint Antibody Pilatus Biosciences has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PLT012, a first-in-class, humanized anti-CD36 monoclonal ant...
Read More...
Dec 15, 2025
Cushing’s Disease Treatment: A New Era of Therapeutic Possibilities
Cushing’s disease is a rare but serious endocrine disorder caused by a pituitary adenoma that leads to excessive secretion of ACTH. This condition results in abnormally high cortisol levels in the body, causing a cascade of serious health complications. Cushing’s syndrome, the clinical manifestation of this disorde...
Read More...
Dec 12, 2025
Limited Refractory Chronic Cough Treatment Landscape: LYFNUA Approval Restricted to Europe and Japan
Refractory chronic cough (RCC) is characterized by ongoing coughing that persists even after comprehensive evaluation and appropriate management of all identifiable underlying causes, pointing to an underlying neurogenic cough hypersensitivity. It is clinically distinct from other forms of chronic cough, and diagno...
Read More...
Dec 11, 2025
A New Star at SABCS 2025: BioNTech–BMS’s Pumitamig Redefines Next-Gen Immunotherapy
The 2025 San Antonio Breast Cancer Symposium (SABCS), the world’s leading forum for breast cancer research, highlights cutting-edge progress across the full spectrum of breast cancer, from prevention and molecular biology to new therapies and survivorship. This year’s focus includes several emerging strategies to r...
Read More...